1. Preface

   • E. F. Stange
   • H. H. Ditschuneit
   • K. von Bergmann

   EditorialNotes Pages: S1 - S1

2. Indications for lipid-lowering drugs

   • J. Davignon

   OriginalPaper Pages: S3 - S10

3. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin

   • Y. Chao
   • J. S. Chen
   • A. W. Alberts

   OriginalPaper Pages: S11 - S14

4. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase

   • H. Y. Pan

   OriginalPaper Pages: S15 - S18

5. Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor

   • T. A. Miettinen

   OriginalPaper Pages: S19 - S21

6. Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia

   • M. J. Tikkanen
   • J. -P. Ojala
   • E. Helve

   OriginalPaper Pages: S23 - S25

7. Comparison of different HMG-CoA reductase inhibitors

   • H. H. Ditschuneit
   • K. Kuhn
   • H. Ditschuneit

   OriginalPaper Pages: S27 - S32

8. Effects of bezafibrate on hepatic cholesterol metabolism

   • D. Ståhlberg
   • E. Reihnér
   • B. Angelin

   OriginalPaper Pages: S33 - S36

9. Bezafibrate fails to directly modulate HMG-CoA reductase or LDL catabolism in human mononuclear cells

   • E. F. Stange
   • M. Frühholz
   • H. Ditschuneit

   OriginalPaper Pages: S37 - S40

10. Fibrates and triglyceride metabolism

    • P. Schwandt

    OriginalPaper Pages: S41 - S43

11. Increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia

    • G. Franceschini
    • F. Bernini
    • C. R. Sirtori

    OriginalPaper Pages: S45 - S48

12. Coronary drug project: experience with niacin

    • K. G. Berge
    • P. L. Canner
    • The Coronary Drug Project Research Group

    OriginalPaper Pages: S49 - S51

13. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism

    • K. Einarsson
    • S. Ericsson
    • B. Angelin

    OriginalPaper Pages: S53 - S58

14. Mechanisms of action of plant sterols on inhibition of cholesterol absorption

    • T. Heinemann
    • G. -A. Kullak-Ublick
    • K. von Bergmann

    OriginalPaper Pages: S59 - S63

15. Inhibition of cholesterol absorption by neomycin, benzodiazepine derivatives and ketoconazole

    • Y. A. Kesäniemi
    • T. A. Miettinen

    OriginalPaper Pages: S65 - S67

16. The Lipid Research Clinics Coronary Primary Prevention Trial: design, results, and implications

    • J. L. Probstfield
    • B. M. Rifkind

    OriginalPaper Pages: S69 - S75

17. Antiatherosclerotic effect of probucol in WHHL rabbits: are there plasma parameters to evaluate this effect?

    • B. Finckh
    • A. Niendorf
    • U. Beisiegel

    OriginalPaper Pages: S77 - S80

18. Clinical and therapeutic use of probucol

    • A. Berg
    • M. W. Baumstark
    • J. Keul

    OriginalPaper Pages: S81 - S84

19. Beclobrate: pharmacodynamic properties and therapeutic use in hyperlipidemia

    • C. Wanner
    • H. Wieland
    • W. H. Hörl

    OriginalPaper Pages: S85 - S89

20. Clinical pharmacology of the hypocholesterolemic agent K 12.148 (lifibrol) in healthy volunteers

    • H. Hasibeder
    • H. J. Staab
    • W. März

    OriginalPaper Pages: S91 - S94